Protocol Ledger

NCT07000084 · Phase III · RECRUITING

Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy

Interventional Phase III clinical trial protocol NCT07000084 sponsored by Alliance for Clinical Trials in Oncology in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-07-17 Enrollment: 330 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07000084
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)330 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07000084
Protocol FieldVerified Registry Value
NCT IdentifierNCT07000084
Consolidated Lead SponsorAlliance for Clinical Trials in Oncology
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment330 participants (ESTIMATED)
Registered Start Date2025-07-17
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI